Movement Alert｜Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities

Market Focus06-24

On June 24, Hansoh Pharmaceutical rose 3.18% in regular trading, trading at 30.38 HKD/share, with turnover of approximately 180 million HKD.

On the news front, Guosheng Securities recently initiated coverage on Hansoh Pharmaceutical with a Buy rating and a target price of 40.61 HKD, implying a 37x P/E multiple and approximately 33% upside from current levels. Additionally, the company's self-developed GLP-1/GIP dual-target weight-loss drug Olebopatide has had its NDA accepted by China's NMPA for long-term weight management in obese or overweight adults. Phase III clinical data demonstrated a maximum weight reduction of 19.3% at 48 weeks with a nausea incidence below 10%, exhibiting strong efficacy and favorable tolerability. Related mechanistic research was also presented at the global endocrinology conference ENDO. The company reported full-year revenue of approximately RMB 15.03 billion, up 22.6% year-over-year, with net profit of RMB 5.56 billion, up 27.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175832743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175832743","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities","media":"Market Focus","content":"<p><p>On June 24, Hansoh Pharmaceutical rose 3.18% in regular trading, trading at 30.38 HKD/share, with turnover of approximately 180 million HKD.</p><p>On the news front, Guosheng Securities recently initiated coverage on Hansoh Pharmaceutical with a Buy rating and a target price of 40.61 HKD, implying a 37x P/E multiple and approximately 33% upside from current levels. Additionally, the company's self-developed GLP-1/GIP dual-target weight-loss drug Olebopatide has had its NDA accepted by China's NMPA for long-term weight management in obese or overweight adults. Phase III clinical data demonstrated a maximum weight reduction of 19.3% at 48 weeks with a nausea incidence below 10%, exhibiting strong efficacy and favorable tolerability. Related mechanistic research was also presented at the global endocrinology conference ENDO. The company reported full-year revenue of approximately RMB 15.03 billion, up 22.6% year-over-year, with net profit of RMB 5.56 billion, up 27.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Hansoh Pharmaceutical rose 3.18% in regular trading, trading at 30.38 HKD/share, with turnover of approximately 180 million HKD.</p><p>On the news front, Guosheng Securities recently initiated coverage on Hansoh Pharmaceutical with a Buy rating and a target price of 40.61 HKD, implying a 37x P/E multiple and approximately 33% upside from current levels. Additionally, the company's self-developed GLP-1/GIP dual-target weight-loss drug Olebopatide has had its NDA accepted by China's NMPA for long-term weight management in obese or overweight adults. Phase III clinical data demonstrated a maximum weight reduction of 19.3% at 48 weeks with a nausea incidence below 10%, exhibiting strong efficacy and favorable tolerability. Related mechanistic research was also presented at the global endocrinology conference ENDO. The company reported full-year revenue of approximately RMB 15.03 billion, up 22.6% year-over-year, with net profit of RMB 5.56 billion, up 27.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1175832743","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175832743","pubTimestamp":1782268579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Hansoh Pharmaceutical rose 3.18% in regular trading, trading at 30.38 HKD/share, with turnover of approximately 180 million HKD.On the news front, Guosheng Securities recently initiated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"异动快讯|豪森药业常规交易涨3.18%获国盛证券首次买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On June 24, Hansoh Pharmaceutical rose 3.18% in regular trading, trading at 30.38 HKD/share, with turnover of approximately 180 million HKD.On the news front, Guosheng Securities recently initiated coverage on Hansoh Pharmaceutical with a Buy rating and a target price of 40.61 HKD, implying a 37x P/E multiple and approximately 33% upside from current levels. Additionally, the company's self-developed GLP-1/GIP dual-target weight-loss drug Olebopatide has had its NDA accepted by China's NMPA for long-term weight management in obese or overweight adults. Phase III clinical data demonstrated a maximum weight reduction of 19.3% at 48 weeks with a nausea incidence below 10%, exhibiting strong efficacy and favorable tolerability. Related mechanistic research was also presented at the global endocrinology conference ENDO. The company reported full-year revenue of approximately RMB 15.03 billion, up 22.6% year-over-year, with net profit of RMB 5.56 billion, up 27.1%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175832743","isCrawlerRequest":true}